Overview

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

Status:
Completed

Trial end date:
2020-11-10

Target enrollment:

Participant gender:

Summary

The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Collaborators:

AstraZeneca
Daiichi Sankyo, Inc.

Treatments:

Trastuzumab